Hi t4p, Yes, the lack of recent announcements provided an excellent period of accumulation at suppressed price levels.
I agree that news from several angles might be shortly forthcoming, this expectation is strongly contributing to my decision to stop trading ANP in the short term. It was fun while it lasted...
Within that expectation I find of particular interest wether a positive partner response involving ATL1101 for prostate cancer treatments alludes to a higher possibility for ATL1103 being developed towards cancer treatment as well, or the other way round, corporate news about ATL1103 including cancer treatment trials making a positive development for ATL1101 more likely.
Whichever news come first, they should increase the outcome of the other.
ANP having a strong foot in complimentary oncological treatments would spiral the shareprice pretty much out of control.
With the latest ATL1102 application exploring the option of stem cell mobilisation used for generating excess stems cells for storage to replenish the patient after chemotherapy further supports that ANP is actively targeting the cancer treatment market.
The chances of finding a new partner for the MS program for ATL1102 might increase after successful ATL1103 phase 1 results.
The first positive news might therefore be the onset of a row of great updates to expect.
All in all, not a company to watch from the sidelines with so much going on lately. I want to express my gratitude towards your shared knowledge of the company which contributed greatly to my own research.
ANP Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
